Zollinger Ellison Syndrome

Short summary: Zollinger-Ellison syndrome is the clinical picture caused by excessive gastrin secretion from tumors called gastrinomas, leading to marked gastric acid overproduction. This may cause refractory ulcers, reflux symptoms, abdominal pain, and diarrhea. ^[1][2]

Short summary: Although rare, delayed diagnosis matters because prolonged acid burden can lead to gastrointestinal complications, while tumor spread may create oncologic problems. Management therefore focuses both on suppressing acid and on locating and staging the gastrinoma. ^[1][3]

At the center of Zollinger-Ellison syndrome is the gastrinoma. These neuroendocrine tumors most often arise in the duodenum or pancreas and secrete gastrin in an uncontrolled manner. Gastrin normally stimulates gastric acid production after meals, but when present in excessive amounts it drives acid levels beyond the usual physiologic range. The result may be peptic ulcers, esophagitis, severe reflux, and other acid-related problems. ^[1][2][4]

Some patients present with classic ulcer symptoms: burning or gnawing upper abdominal pain, heartburn, nausea, and sometimes signs of gastrointestinal bleeding. However, diarrhea is also an important symptom in Zollinger-Ellison syndrome and may be the dominant complaint in some people. Excess acid disrupts the small-intestinal environment and affects digestion. Unlike routine ulcer disease, recurrent, multiple, or treatment-resistant ulcers should heighten suspicion for this syndrome. ^[1][2]

An important aspect of this syndrome is its association in some cases with multiple endocrine neoplasia type 1 (MEN1). In MEN1, parathyroid, pituitary, and pancreatic/duodenal neuroendocrine tumors may occur together. For that reason, a syndromic association should be considered in younger patients, those with multiple lesions, or those with a family history suggestive of MEN1. The presence of MEN1 can change both diagnostic planning and long-term follow-up. ^[2][4]

Diagnosis involves more than measuring gastrin alone. Proton pump inhibitor use, atrophic gastritis, and other conditions can also elevate gastrin levels. When clinical suspicion is high, fasting gastrin level, gastric pH assessment, and, in selected cases, secretin testing are interpreted together. Diagnostic thresholds require experience; for example, a very high gastrin level accompanied by low gastric pH is much more meaningful. ^[2][4]

Imaging is crucial for locating the tumor and evaluating spread. Endoscopy can show ulcers and mucosal injury, but cross-sectional imaging and nuclear medicine methods may be needed to identify gastrinomas. Modern assessment may include somatostatin receptor imaging and, in selected cases, endoscopic ultrasound. The goal is to identify both the primary lesion and metastatic spread, especially to the liver. ^[2][4]

The first pillar of treatment is acid control. Proton pump inhibitors can markedly reduce acid burden and thereby improve ulcers, pain, and reflux symptoms. Although these drugs may partially mask the picture before diagnosis and therefore must be handled carefully during work-up, they remain powerful tools for preventing complications once the diagnosis is established. The aim is not only symptom relief but also prevention of bleeding, perforation, and stricture related to excess acid. ^[1][2]

The second pillar is tumor-directed management. In localized gastrinoma, surgical resection may offer the possibility of cure. Not every patient is a surgical candidate, however, and some have multiple small duodenal foci or metastatic disease. In metastatic or advanced neuroendocrine tumors, somatostatin analogs, targeted therapies, liver-directed interventions, and broader oncologic strategies may become relevant. For this reason, care is often multidisciplinary, involving gastroenterology, endocrinology, surgery, and oncology. ^[1][2][4]

Complications can be considered in two main groups: those related to excess acid and those related to tumor biology. Persistent acid overproduction can cause ulcers, esophagitis, upper gastrointestinal bleeding, perforation, and strictures. On the oncologic side, gastrinomas may behave malignantly and especially metastasize to the liver. The syndrome should therefore not be viewed merely as “too much acid”; tumor size and extent of spread are also central. ^[1][2]

Medical evaluation becomes particularly important in people with recurrent or treatment-resistant ulcers. Repeated ulcers despite standard treatment, unexplained chronic diarrhea, multiple ulcers, severe reflux, or a family history of MEN1 should prompt further investigation. Vomiting blood, black stools, sudden severe abdominal pain, or weight loss may require urgent medical care. ^[1][2][3]

Although rare, Zollinger-Ellison syndrome is manageable once recognized. The course varies from person to person; in some cases acid control dominates management, whereas in others tumor burden is the main determinant. Individualized assessment and long-term follow-up are therefore important. In people with recurrent ulcers or unexplained diarrhea, a detailed search for the underlying cause may help prevent delayed diagnosis. ^[1][2][4]